Eyevensys
Platforms for long acting non-viral gene therapy for ocular diseases
Total raised
€46M
€46,205,518
Funding rounds
5
Investors
5
distinct backers
Active since
2013-03
latest 2021-08
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood15
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood22
base rate 12% (2+ rounds)
- ▲ 5 rounds raised
- ▲ €30M+ raised
- ▲ 18y since founding
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
5 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-09 | Series B | €10M | Korea Investment Partners | View deal → |
| 2020-08-01 | Series B | €27M | Boehringer Ingelheim Venture Fund | View deal → |
| 2016-09-01 | Series A | €9.0M | Pontifax Funds | View deal → |
| 2015-06-01 | Seed | €0 | CapDecisif Management,Inserm Transfert Initiative | View deal → |
| 2013-04-01 | Early VC | €0 | Boehringer Ingelheim Venture Fund | View deal → |
Investors
5Related news
- Eyevensys Raises $12M in Series B+ Fundingfinsmes.com · 2021-08
- finsmes.com
- dallasnews.com
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software